Skip to content
Aurenex

Clinical research · Clinical

Detecting phase III data risk eleven days earlier

Cross-source anomaly detection across EDC, labs and eCOA that cut query volume while catching issues sooner.

The challenge

Data quality issues were being detected at monthly review, by which point corrective action at sites was slow and expensive.

What we did

  1. 01Unified EDC, central lab and eCOA streams into one review model
  2. 02Trained anomaly detection on historical study deviations
  3. 03Deployed the Study Conduct Agent with explicit escalation rules
  4. 04Instrumented every escalation for false-positive review

Results

Earlier detection
11 days
Query volume
-38%
Monitoring cost
-21%

Client: Mid-cap clinical sponsor

Next step

Bring a real problem. We will bring the architecture.

Thirty minutes with our architects is usually enough to tell whether a programme is ready for agents, or whether the data foundation needs work first.

Talk to an architect
See the work